Cancer data sharing improves cancer research and treatment access by enabling oncologists, clinical investigators, and healthcare institutions to exchange patient information, trial data, and real-world outcomes securely and efficiently, which leads to faster trial enrollment, more accurate treatment decisions, and better patient outcomes across both community and academic care settings. When physicians have access to shared oncology data, they can identify the right treatment options for each patient without the delays and information gaps that have long made clinical trial participation unnecessarily difficult.

Why the Current System Falls Short

Only 7% of adult cancer patients in the United States participate in clinical trials. This number has remained low for years, and the reasons are well-documented. Community oncologists often do not hear about relevant trials in time. Patients lose touch with their treating physician once they are referred elsewhere. Institutions operate in isolation, sharing little data with the broader oncology community.

The consequences of this fragmentation are significant. Patients miss treatment options that could extend or save their lives. Clinical trials take longer to enroll, which delays the availability of new therapies for everyone. Oncologists are left to navigate an overwhelming volume of evolving trial information without the tools or time to do so effectively.

Cancer data sharing directly addresses this problem. When patient information, molecular profiles, and trial eligibility data flow between institutions through secure, standardized platforms, the entire care ecosystem becomes more responsive, more accurate, and more equitable.

What Cancer Data Sharing Actually Involves

Cancer data sharing is the structured, consented exchange of oncology-relevant information across care settings. This is not about sharing information carelessly. It operates within established regulatory frameworks, requires patient consent, and relies on technical standards designed to protect privacy while enabling meaningful collaboration.

The types of data involved include treatment histories and clinical outcomes from routine care, biomarker and genomic testing results, clinical trial eligibility criteria and enrollment records, and care coordination notes shared between treating physicians and research teams.

When these data streams are connected through oncology data sharing platforms, physicians gain a fuller picture of each patient’s situation, and researchers gain access to the real-world evidence that controlled trials alone cannot generate.

Connect with the 1104Health Shared Care Network and give your patients access to the trials they deserve. Join here: https://1104health.com/local-physicians/

How Data Sharing Improves Cancer Treatment Outcomes

1. More Precise Clinical Trial Matching

The most immediate benefit of cancer research data exchange is the ability to match patients to relevant clinical trials based on their actual clinical profiles rather than broad diagnosis categories. When a physician’s practice is connected to a network that aggregates trial eligibility criteria and patient data, appropriate trials are surfaced automatically.

This removes the burden of manual research from the physician and eliminates the delays that occur when trial awareness depends on conference attendance or personal networks. Patients who might otherwise never have been considered for a trial become visible to the right investigators at the right time.

2. Coordinated Care Across Institutions

Oncology care is rarely confined to a single provider. Patients see community oncologists, subspecialists, and clinical investigators, often at different institutions with separate record systems. Without data sharing, critical information gets repeated, delayed, or lost during transitions.

When physicians share clinical data through a structured network, care coordination becomes proactive rather than reactive. The treating oncologist stays informed about the patient’s progress even when care is temporarily transferred, and the patient returns to their original physician with complete documentation rather than gaps in their history.

This approach is central to what 1104Health has built through its Shared Care Network, a physician-first model that keeps community oncologists connected, informed, and at the center of every patient’s journey throughout a clinical trial.

Real-World Cancer Data Sharing: Why It Matters for Research

Clinical trials are carefully controlled studies designed to answer specific research questions. They provide essential evidence, but they also have limitations. Trial populations tend to be younger, healthier, and less diverse than the full population of cancer patients receiving care in community settings.

Real-world cancer data sharing addresses this limitation by aggregating information from routine clinical care across many institutions. When de-identified patient records from diverse communities are combined and analyzed within appropriate governance frameworks, they generate evidence that controlled trials cannot replicate.

This kind of population-level analysis has already contributed to a deeper understanding of how certain therapies perform in older patients with multiple comorbidities, how long-term survival rates compare between trial and non-trial populations, and which patient subgroups respond most consistently to specific treatment regimens.

None of this is possible when data stays within institutional walls. It requires the kind of coordinated oncology data sharing that, until recently, the industry lacked the infrastructure to support at scale.

The Role of AI in Cancer Data Analysis and Research

Artificial intelligence is transforming oncology, but its value depends almost entirely on the quality and breadth of the data it has access to. The role of AI in cancer data analysis and research is to identify patterns in large, complex datasets that would be impossible for clinicians to recognize manually. This includes predicting which patients are likely to respond to a given therapy, flagging individuals who meet eligibility criteria for open trials, and identifying early signals of treatment resistance or adverse events.

An AI model trained only on data from one academic medical center will reflect the specific patient population, documentation practices, and treatment preferences of that institution. When the same model is trained on shared, multi-institutional data that spans diverse geographies and patient populations, its predictive accuracy improves substantially, and its findings become relevant to a broader range of patients and care settings.

At 1104Health, AI-assisted prescreening helps physicians identify patients who may qualify for clinical trials without requiring manual review of every open study. This means more patients are considered, more efficiently, with less administrative effort from the clinical team.

How Clinical Trial Data Is Shared Between Hospitals

Understanding how clinical trial data is shared between hospitals helps clarify both the progress that has been made and the challenges that remain.

Several mechanisms are currently in use across the oncology community:

• Data Use Agreements (DUAs): Formal contracts between institutions that define the terms under which patient information can be accessed and analyzed for research purposes.
  
• Common Data Models: Standardized formats such as OMOP and FHIR allow data from different electronic health record systems to be mapped to a consistent structure, making it possible to run analyses across disparate platforms.
  
• Federated Analysis: An approach in which data never leaves the originating institution. Analytical algorithms are run locally, and only the results are shared, which protects patient privacy while enabling cross-institutional insights.
  
• Oncology Collaboration Platforms: Physician-facing tools that enable real-time sharing of patient data, trial eligibility information, and care coordination notes within a network of trusted providers.

Each approach has trade-offs, and the most effective data-sharing systems combine multiple methods to balance privacy protection with the speed and granularity that clinical use requires.

Healthcare Data Interoperability in Oncology

Healthcare data interoperability in oncology refers to the ability of different health information systems to exchange and make use of data in a consistent, standardized way. It is the technical infrastructure that makes cancer data sharing possible at scale.

When oncology systems are interoperable, a community oncologist can access a complete picture of a patient’s prior treatment history regardless of where that care was delivered. A clinical investigator can conduct accurate prescreening without requesting manual records from multiple institutions. A patient navigating a trial referral does not have to repeat their history at every appointment.

The benefits extend across the care continuum:

• Physicians make better-informed decisions because no prior information is missing
• Investigators enroll appropriate patients more quickly because eligibility screening is accurate and efficient
• Patients experience fewer delays and less administrative friction as their care moves across settings
• Payers and employers gain access to real-world outcome data that supports evidence-based coverage decisions

1104Health is built on this foundation. The platform connects community oncologists with academic medical centers, research investigators, and subspecialists through a shared care model that standardizes communication and keeps every member of the care team aligned throughout the patient’s treatment journey.

Frequently Asked Questions

1. What is cancer data sharing and why does it matter for oncologists?

Cancer data sharing is when doctors, hospitals, and research teams share patient information, trial records, and treatment results with each other in a secure and consented way. For oncologists, this is important because it helps them find the right treatment or trial for their patient without spending hours hunting for information. It also means they can lean on the broader medical community rather than making complex decisions in isolation.

2. How does data sharing help improve clinical trial enrollment rates?

Right now, most oncologists hear about trials through conferences or colleagues, which means many patients never even get considered. When data systems are connected, physicians get notified about trials that actually fit their patients. The process moves from reactive to proactive, and more patients end up in trials that could genuinely help them.

3. Is patient privacy protected when oncology data is shared?

Yes, completely. All data sharing in the U.S. follows HIPAA regulations. Patients give their consent before anything is shared. For research purposes, personal identifying details are removed from the data. Hospitals and institutions also sign formal agreements with each other before any exchange happens, so there is a clear layer of accountability throughout the process.

4. What role does AI play in oncology data sharing?

AI helps physicians go through large amounts of patient data much faster than any manual process would allow. It can highlight which patients may be a good fit for an open trial, or show patterns across hundreds of cases that would otherwise go unnoticed. When more institutions share data, these tools become more reliable and useful for a wider range of patients.

5. How does 1104Health support cancer data sharing for community oncologists?

1104Health brings community oncologists into a connected network where they can collaborate with investigators and subspecialists, access relevant clinical trials, and coordinate patient care without the usual administrative headaches. Patient prescreening and care coordination are handled through the platform. Physicians are paid fairly for their time, and joining costs nothing.